文献速递肾小球疾病慢性肾脏病

尿基质金属蛋白酶7与IgA肾病进展预测

Urinary Matrix Metalloproteinase 7 and Prediction of IgA Nephropathy Progression.
PubMed 文献 · Am J Kidney Dis · 2019-10-09

该前瞻性观察队列研究纳入946例中国IgA肾病患者,发现尿MMP-7高水平(>3.9μg/g肌酐)与IgA肾病进展风险增加2.7倍独立相关。将尿MMP-7加入活检时临床数据及MEST-C评分可显著改善风险预测,C统计量从0.79升至0.85,外部验证集结果一致。

要点

  • 尿MMP-7>3.9μg/g肌酐者IgA肾病进展风险增加2.7倍。
  • 尿MMP-7预测效能优于尿AGT、EGF、KIM-1及血清Gd-IgA1。
  • 联合尿MMP-7可显著提升MEST-C和临床数据的风险预测。

核心结论

  • 尿MMP-7是IgA肾病进展的独立预测因子。
  • 在活检时临床数据和MEST-C评分基础上加入尿MMP-7可显著改善进展风险预测。

研究设计与样本

  • 前瞻性观察队列研究,中国946例IgA肾病患者,训练集554例中位随访40个月,验证集392例中位随访28个月。

主要发现

  • 尿MMP-7>3.9μg/g肌酐与IgA肾病进展风险增加2.7倍相关(校正分析)。
  • 尿MMP-7预测IgA肾病进展的C统计量为0.78,优于尿AGT(0.75)、EGF(0.75)、KIM-1(0.68)和血清Gd-IgA1(0.59)。
  • 将尿MMP-7加入活检时临床数据(eGFR、平均动脉压、蛋白尿)和MEST-C评分模型,C统计量从0.79提高至0.85。
  • 加入尿MMP-7后3年风险预测C统计量从0.84提高至0.90,类别无净重分类改善指数为0.60。
  • 尿MMP-7单独或联合临床数据的预测性能在外部验证集中一致。

临床怎么用

  • 对于IgA肾病患者,活检时检测尿MMP-7可能有助于早期识别进展高风险患者。
  • 将尿MMP-7纳入活检时临床数据和MEST-C评分可改善风险分层,指导临床决策。

局限性

  • 缺乏在其他种族人群中的验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: A major challenge in the management of immunoglobulin A nephropathy (IgAN) is the inability to identify patients at high risk for disease progression at an early stage. Our objective was to determine whether urinary matrix metalloproteinase 7 (MMP-7) is a promising predictor for IgAN progression and whether its addition to clinical data at the time of biopsy improves risk prediction. STUDY DESIGN: Prospective observational cohort study in China. SETTING & PARTICIPANTS: 946 Chinese patients with IgAN followed up for a median of 40 months in 1 clinical center serving as the training set (n=554) and for 28 months in a second clinical center serving as the validation set (n = 392). PREDICTORS: Urinary MMP-7 and 7 previously reported biomarkers measured at the time of kidney biopsy and a score of histologically defined disease severity (MEST-C). OUTCOMES: IgAN progression was defined as a composite of >40% loss of estimated glomerular filtration rate, kidney failure, or death. ANALYTICAL APPROACH: Cox proportional hazard models adjusted for clinical characteristics, kidney function, relevant medications, and MEST-C score. Risk classification statistics were calculated for IgAN progression at 3 years, including C statistic, net reclassification index, and integrated discrimination index. RESULTS: High levels (>3.9μg/g of creatinine) of urinary MMP-7 were associated with a 2.7-fold higher risk for IgAN progression in adjusted analyses. Urinary MMP-7 level outperformed (C statistic, 0.78) levels of urinary angiotensinogen (C statistic, 0.75), epidermal growth factor (C statistic, 0.75), kidney injury molecule 1 (C statistic, 0.68), and serum galactose-deficient IgA1 (C statistic, 0.59) for predicting IgAN progression. The addition of urinary MMP-7 level to a model with clinical data from the time of biopsy (estimated glomerular filtration rate, mean arterial blood pressure, and proteinuria) and MEST-C score significantly improved the C statistic from 0.79 to 0.85, improved the 3-year risk prediction of IgAN progression (from 0.84 to C statistic of 0.90), and improved risk reclassification (category-free net reclassification improvement, 0.60). The predictive performance of urinary MMP-7 level, alone or combined with clinical data, was consistent in the external validation set. LIMITATIONS: Lack of validation in other ethnic populations. CONCLUSIONS: In this study cohort, urinary MMP-7 level is an independent predictor of IgAN progression. The addition of urinary MMP-7 level to MEST-C score and clinical data at the time of biopsy significantly improved risk prediction of IgAN progression.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Yang X, Ou J, Zhang H, et al. Urinary Matrix Metalloproteinase 7 and Prediction of IgA Nephropathy Progression. Am J Kidney Dis. 2019. PMID: 31606236. doi:10.1053/j.ajkd.2019.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。